Abstract
Primary brain high-grade gliomas, excluding glioblastoma are rare and heterogeneous tumors, showing different characteristic mutations and a better prognosis than glioblastomas. The addition of chemotherapy to the radiotherapy in the newly diagnosed disease has not been established yet. We treated 9 patients with newly diagnosed tumors with temozolomide at 75 mg/m2 for 7 days a week during standard radiotherapy, followed by six cycles at 200 mg/m2 on days 1-5 every 28 days. Fluorescence in situ hybridization for the 1 p/19 q loss was performed in seven out of the 9 patients. With a median follow-up of 15 months (range, 8-50), eight patients are alive and one died from disease progression. Four patients had disease progression at 7, 15, 14 and 13 months from the diagnosis. The 1 p/19 q loss was found in 5 patients; three have no evidence of disease, one had partial disease remission and one disease progression. Toxicities included one discitis requiring treatment withdrawal and specific antibiotic therapy, and one transient grade 3 psoriasiform reaction. Based on this small series of patients, the addition of temozolomide to radiotherapy may be recommended.
| Original language | English |
|---|---|
| Pages (from-to) | 323-325 |
| Number of pages | 3 |
| Journal | Journal of Neuro-Oncology |
| Volume | 81 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Feb 2007 |
Fingerprint
Keywords
- Adjuvant therapy
- Concomitant therapy
- High-grade glioma
- Malignant glioma
- Radiotherapy
- Temozolomide
ASJC Scopus subject areas
- Clinical Neurology
- Cancer Research
- Oncology
- Neuroscience(all)
Cite this
Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme. / Banna, Giuseppe Luigi; Bettio, Daniela; Scorsetti, Marta; Navarria, Pierina; Simonelli, Matteo; Rodriguez Baena, Riccardo; Aimar, Enrico; Gaetani, Paolo; Colombo, PierGiuseppe; Rognone, Felice; Santoro, Armando.
In: Journal of Neuro-Oncology, Vol. 81, No. 3, 02.2007, p. 323-325.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme
AU - Banna, Giuseppe Luigi
AU - Bettio, Daniela
AU - Scorsetti, Marta
AU - Navarria, Pierina
AU - Simonelli, Matteo
AU - Rodriguez Baena, Riccardo
AU - Aimar, Enrico
AU - Gaetani, Paolo
AU - Colombo, PierGiuseppe
AU - Rognone, Felice
AU - Santoro, Armando
PY - 2007/2
Y1 - 2007/2
N2 - Primary brain high-grade gliomas, excluding glioblastoma are rare and heterogeneous tumors, showing different characteristic mutations and a better prognosis than glioblastomas. The addition of chemotherapy to the radiotherapy in the newly diagnosed disease has not been established yet. We treated 9 patients with newly diagnosed tumors with temozolomide at 75 mg/m2 for 7 days a week during standard radiotherapy, followed by six cycles at 200 mg/m2 on days 1-5 every 28 days. Fluorescence in situ hybridization for the 1 p/19 q loss was performed in seven out of the 9 patients. With a median follow-up of 15 months (range, 8-50), eight patients are alive and one died from disease progression. Four patients had disease progression at 7, 15, 14 and 13 months from the diagnosis. The 1 p/19 q loss was found in 5 patients; three have no evidence of disease, one had partial disease remission and one disease progression. Toxicities included one discitis requiring treatment withdrawal and specific antibiotic therapy, and one transient grade 3 psoriasiform reaction. Based on this small series of patients, the addition of temozolomide to radiotherapy may be recommended.
AB - Primary brain high-grade gliomas, excluding glioblastoma are rare and heterogeneous tumors, showing different characteristic mutations and a better prognosis than glioblastomas. The addition of chemotherapy to the radiotherapy in the newly diagnosed disease has not been established yet. We treated 9 patients with newly diagnosed tumors with temozolomide at 75 mg/m2 for 7 days a week during standard radiotherapy, followed by six cycles at 200 mg/m2 on days 1-5 every 28 days. Fluorescence in situ hybridization for the 1 p/19 q loss was performed in seven out of the 9 patients. With a median follow-up of 15 months (range, 8-50), eight patients are alive and one died from disease progression. Four patients had disease progression at 7, 15, 14 and 13 months from the diagnosis. The 1 p/19 q loss was found in 5 patients; three have no evidence of disease, one had partial disease remission and one disease progression. Toxicities included one discitis requiring treatment withdrawal and specific antibiotic therapy, and one transient grade 3 psoriasiform reaction. Based on this small series of patients, the addition of temozolomide to radiotherapy may be recommended.
KW - Adjuvant therapy
KW - Concomitant therapy
KW - High-grade glioma
KW - Malignant glioma
KW - Radiotherapy
KW - Temozolomide
UR - http://www.scopus.com/inward/record.url?scp=33846502804&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846502804&partnerID=8YFLogxK
U2 - 10.1007/s11060-006-9234-x
DO - 10.1007/s11060-006-9234-x
M3 - Article
C2 - 17031557
AN - SCOPUS:33846502804
VL - 81
SP - 323
EP - 325
JO - Journal of Neuro-Oncology
JF - Journal of Neuro-Oncology
SN - 0167-594X
IS - 3
ER -